DALLAS, Nov. 12 /PRNewswire-FirstCall/ -- HaloLaser Biotherapy, LLC, is pleased to announce the signing of a letter of intent to acquire the ongoing customer base, inventory, patents and patents pending of MEDICARDIUM, Inc., which is expected to be included in the merger agreement between HaloLaser and Corbel Holdings Inc. (Pink Sheets: CBLH).
MEDICARDIUM, Inc. is a privately held Panamanian corporation, which was formed in 2000. MEDICARDIUM(TM) is an over-the-counter chelation therapy product. Medicardium Chelation is a proprietary patented product used by a person to remove metal toxicity, aid circulatory disorders, diabetes and aging. The FDA has not made any evaluation of the Medicardium product. Medicardium has had 4 prior years of increased annual revenues and is estimated to have $500,000 in Gross Sales for 2005.
Additionally, a new patent pending physical therapy table called the Vibraboard(TM) will be an integral part of the assets in the merger. The Vibraboard(TM) provides Biomechanical Stimulation (BMS) as a therapeutic modality. The Vibraboard(TM) is primarily used by medical practitioners to help increase the strength and coordination of the musculoskeletal and nervous systems and to increase the rate at which an injured person heals.
HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc., announced earlier that they were to enter an agreement to facilitate a reverse merger of HaloLaser Biotherapy LLC and Charles R. Crane MD and Associates into Corbel Holdings, Inc. for purposes of taking control and functioning on its own merits and being identified as a legal trading company. Corbel Holdings, Inc., HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc. are in a due diligence period before the closing of the transaction.
HaloLaser Biotherapy LLC in Dallas, Texas is in the biotech medical healthcare alternative pain management business of treating patients with acute pain and arthritis with the new FDA approved Neurolase 150 Medical laser device.
Keith Houser, President and CEO of HaloLaser stated, “The products incorporated with the Medicardium merger bring proven proprietary alternative pain management products to our growing company that will demonstrably improve one’s quality of life. This will give us a competitive edge in the field of pain management.” Additional information on HaloLaser can be found on the Internet at http://www.halolaser.com/. Additional information on Medicardium can be found at http://www.medicardium.com/.
Bruce Harlan, President and CEO of Corbel Holdings, Inc., stated, “We are elated to have the Medicardium assets and ongoing business of Medicardium incorporated in the Halo Laser and Charles R. Crane MD and Associates Inc., merger into Corbel Holdings.”
Safe Harbor:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words “plan,” “confident that,” “believe,” “scheduled,” “expect,” or “intend to,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the Company to complete the planned bridge financing, market conditions, the general acceptance of the Company’s products and technologies, competitive factors, timing and other risks described in the Company’s SEC reports and filings.
Corbel Holdings Inc.
CONTACT: Bruce Harlan of Corbel Holdings Inc., +1-702-326-2805; or KeithHouser of HaloLaser Biotherapy LLC, +800-200-2458
Web site: http://www.halolaser.com/
Web site: http://www.medicardium.com/